港股異動 | 歡喜傳媒(01003.HK)漲逾5% 與中國移動旗下咪咕文化展開戰略合作
格隆匯9月29日丨歡喜傳媒(01003.HK)漲逾5%,報1.45港元,總市值53億港元。歡喜傳媒發佈公吿,於2021年9月28日,集團與中國移動通信集團有限公司旗下全資附屬公司咪咕文化科技有限公司在北京成功舉辦了5G觀影、未來同屏戰略合作發佈會,雙方簽署了合作協議,將在多方面展開合作。此次集團與中國移動旗下咪咕文化的合作,依託中國移動魔百和的1.6億用户規模及5G科技賦能,以打造規模巨大的數字院線,進一步打通歡喜首映的流量,用户覆蓋面多領域拓展,把歡喜首映的優質影視內容推廣給更廣泛的觀眾,相信能令歡喜首映APP用户量有顯着的增長,加速釋放歡喜首映平台的價值。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.